SNTA has a fat PIPELINE which will make their first approval possibly move them to $100
Synta has a pipeline of five diverse, novel small molecule programs in two major therapeutic areas: cancer and autoimmune/inflammatory disease. All our compounds were internally discovered and developed and are currently 100% owned by Synta.
We seek to expand the potential of our pipeline by selectively partnering program rights, by geography or by indication, where we believe partnerships can enhance the total value of the program.
Our most clinically advanced program is ganetespib, a potent, synthetic, small molecule inhibitor of heat shock protein 90 (Hsp90) that is currently being studied in multiple clinical trials including a Phase 2b/3 registration-enabling trial in combination with docetaxel in non-small cell lung cancer.
Synta is also developing small-molecule drugs targeting a novel family of ion channels that are critical to immune cell function, known as calcium release-activated calcium modulator (CRACM) channels. The goal is to develop a novel category of oral, disease-modifying agents for the treatment of rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD), allergy, transplant rejection, and other autoimmune diseases and inflammatory conditions.
Other Synta programs include:
Elesclomol, a first-in-class, investigational drug candidate that triggers programmed cell death (apoptosis), in cancer cells through a novel mechanism: disrupting cancer cell energy metabolism by selectively targeting the electron transport chain in cancer cell mitochondria. Elesclomol is currently being studied in a Phase 1 trial in acute myeloid leukemia as well as a Phase 2 trial in combination with paclitaxel in ovarian cancer that is being conducted by the Gynecologic Oncology Group (GOG).
STA-9584, a Vascular Disrupting Agent (VDA) currently being developed through a $1 million grant under the Department of Defense Prostate Cancer Research Program (PCRP) of the Office of the Congressionally Directed Medical Research Programs (CDMRP. This funding supports the study of STA-9584 in advanced prostate cancer.
Our small molecule drug candidates that inhibit the production of the cytokines interleukin-12 (IL-12), and interleukin-23 (IL-23), which are believed to be important regulators of the biological processes underlying certain autoimmune and inflammatory diseases. The IL-12 cytokine family (including IL-12 and IL-23) is the master regulator of the TH1 pathway which drives major chronic inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and multiple sclerosis.
We have an extensive intellectual property portfolio consisting of over 700 issued or pending patents. All Synta compounds currently in clinical trials represent novel chemical structures protected by issued or allowed composition of matter patents, as well as a robust package of related structure, mechanism, formulation, manufacturing, and administration patents.
For further information on partnering or licensing opportunities, please contact:
Christian Cortis, Ph.D.
Head of Business Development
Synta Pharmaceuticals Corp.
45 Hartwell Avenue
Lexington MA, 02421
ccortis AT syntapharma.com
tel: 781-541-7234
[Top of page]
